Astrana Health Statistics
Total Valuation
Astrana Health has a market cap or net worth of $1.86 billion. The enterprise value is $2.44 billion.
| Market Cap | 1.86B |
| Enterprise Value | 2.44B |
Important Dates
The next estimated earnings date is Thursday, November 5, 2026, after market close.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Astrana Health has 51.17 million shares outstanding. The number of shares has increased by 1.73% in one year.
| Current Share Class | 51.17M |
| Shares Outstanding | 51.17M |
| Shares Change (YoY) | +1.73% |
| Shares Change (QoQ) | +1.48% |
| Owned by Insiders (%) | 10.73% |
| Owned by Institutions (%) | 63.41% |
| Float | 38.83M |
Valuation Ratios
The trailing PE ratio is 44.36 and the forward PE ratio is 21.74.
| PE Ratio | 44.36 |
| Forward PE | 21.74 |
| PS Ratio | 0.48 |
| Forward PS | 0.44 |
| PB Ratio | 2.04 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 19.44 |
| P/OCF Ratio | 17.01 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.80, with an EV/FCF ratio of 25.57.
| EV / Earnings | 59.53 |
| EV / Sales | 0.63 |
| EV / EBITDA | 13.80 |
| EV / EBIT | 21.57 |
| EV / FCF | 25.57 |
Financial Position
The company has a current ratio of 1.23, with a Debt / Equity ratio of 1.64.
| Current Ratio | 1.23 |
| Quick Ratio | 1.19 |
| Debt / Equity | 1.64 |
| Debt / EBITDA | 5.09 |
| Debt / FCF | 10.38 |
| Interest Coverage | 1.55 |
Financial Efficiency
Return on equity (ROE) is 6.90% and return on invested capital (ROIC) is 6.24%.
| Return on Equity (ROE) | 6.90% |
| Return on Assets (ROA) | 3.76% |
| Return on Invested Capital (ROIC) | 6.24% |
| Return on Capital Employed (ROCE) | 7.29% |
| Weighted Average Cost of Capital (WACC) | 7.70% |
| Revenue Per Employee | $1.28M |
| Profits Per Employee | $13,516 |
| Employee Count | 3,000 |
| Asset Turnover | 2.06 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Astrana Health has paid $20.87 million in taxes.
| Income Tax | 20.87M |
| Effective Tax Rate | 34.73% |
Stock Price Statistics
The stock price has increased by +29.52% in the last 52 weeks. The beta is 0.91, so Astrana Health's price volatility has been similar to the market average.
| Beta (5Y) | 0.91 |
| 52-Week Price Change | +29.52% |
| 50-Day Moving Average | 37.91 |
| 200-Day Moving Average | 32.35 |
| Relative Strength Index (RSI) | 47.55 |
| Average Volume (20 Days) | 415,017 |
Short Selling Information
The latest short interest is 3.28 million, so 6.41% of the outstanding shares have been sold short.
| Short Interest | 3.28M |
| Short Previous Month | 3.18M |
| Short % of Shares Out | 6.41% |
| Short % of Float | 8.45% |
| Short Ratio (days to cover) | 7.12 |
Income Statement
In the last 12 months, Astrana Health had revenue of $3.84 billion and earned $40.55 million in profits. Earnings per share was $0.82.
| Revenue | 3.84B |
| Gross Profit | 402.00M |
| Operating Income | 111.88M |
| Pretax Income | 60.10M |
| Net Income | 40.55M |
| EBITDA | 174.91M |
| EBIT | 111.88M |
| Earnings Per Share (EPS) | $0.82 |
Balance Sheet
The company has $400.79 million in cash and $979.41 million in debt, with a net cash position of -$578.62 million or -$11.31 per share.
| Cash & Cash Equivalents | 400.79M |
| Total Debt | 979.41M |
| Net Cash | -578.62M |
| Net Cash Per Share | -$11.31 |
| Equity (Book Value) | 598.58M |
| Book Value Per Share | 16.87 |
| Working Capital | 171.52M |
Cash Flow
In the last 12 months, operating cash flow was $107.87 million and capital expenditures -$13.49 million, giving a free cash flow of $94.38 million.
| Operating Cash Flow | 107.87M |
| Capital Expenditures | -13.49M |
| Depreciation & Amortization | 63.03M |
| Net Borrowing | 539.44M |
| Free Cash Flow | 94.38M |
| FCF Per Share | $1.84 |
Margins
Gross margin is 10.46%, with operating and profit margins of 2.91% and 1.05%.
| Gross Margin | 10.46% |
| Operating Margin | 2.91% |
| Pretax Margin | 1.56% |
| Profit Margin | 1.05% |
| EBITDA Margin | 4.55% |
| EBIT Margin | 2.91% |
| FCF Margin | 2.46% |
Dividends & Yields
Astrana Health does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1.73% |
| Shareholder Yield | -1.73% |
| Earnings Yield | 2.21% |
| FCF Yield | 5.14% |
Analyst Forecast
The average price target for Astrana Health is $51.67, which is 42.07% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $51.67 |
| Price Target Difference | 42.07% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | 14.91% |
| EPS Growth Forecast (3Y) | 28.75% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Astrana Health has an Altman Z-Score of 2.63 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.63 |
| Piotroski F-Score | 5 |